Skip to main content
Clinical Trials/NCT01557972
NCT01557972
Unknown
Not Applicable

Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients : Long-term (10 Years) Results of a Prospective Longitudinal Study

Nagaoka Red Cross Hospital1 site in 1 country400 target enrollmentNovember 1999

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes Mellitus
Sponsor
Nagaoka Red Cross Hospital
Enrollment
400
Locations
1
Primary Endpoint
Death
Last Updated
14 years ago

Overview

Brief Summary

Previous cross-sectional studies have demonstrated that blood pressure (BP) measurements at home (HBP) in the morning offer stronger predictive power for micro- and macrovascular complications in patients with type 1 and 2 diabetes than casual/clinic blood pressure measurements (CBP) (Kamoi K et al, 2002-2003). Further, a prospective, longitudinal study for 6 years in patients with type 2 diabetes also demonstrated that control of wakening-up HBP provides the stronger predictive power for the outcomes than that of CBP did (Kamoi et al, 2010).

However, it is not clear to show which of BP measurement provides the stronger predictive power for outcomes by comparing cumulative events over a longer time than 6 years. Therefore, the investigators examined which of HBP or CBP provides the stronger predictive power for outcomes in addition of renal anemia reported previously over 10 years in the patients with type 2 diabetes.

Registry
clinicaltrials.gov
Start Date
November 1999
End Date
March 2013
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kyuzi Kamoi

Investigator

Nagaoka Red Cross Hospital

Eligibility Criteria

Inclusion Criteria

  • After a detailed baseline examination, 400 Japanese subjects with type 2 diabetes reported previously are followed up for all-cause mortality and morbidity.

Exclusion Criteria

  • Other than the above, patients judged inappropriate as the subjects of this study by the investigator

Outcomes

Primary Outcomes

Death

Time Frame: Average time is 10 years

Number of participats not alive

Secondary Outcomes

  • Macrovascular complications(Average time is 10 years)
  • Microvascular complications including renal anemia(Average time is 10 years)

Study Sites (1)

Loading locations...

Similar Trials